Source disclosure: February 10, 2026
Matsuya R&D Co.,Ltd [7317.T]
TOKYO — Matsuya R&D Co., Ltd., listed on the Tokyo Stock Exchange under code number 7317, announced its consolidated third quarter earnings results for the fiscal year ending March 2026 on February 10, 2026. The company reported a slight decline in revenue and mixed performance across other key metrics compared to the same period last year.
For the nine months ended December 31, 2025, Matsuya R&D recorded consolidated sales of ¥7.27 billion, marking a decrease of 1.6% from the previous year's figure of ¥7.39 billion. Operating income improved by 11.1%, reaching ¥1.67 billion against ¥1.50 billion in the corresponding period of 2025. Similarly, ordinary income increased by 11.8% to ¥1.73 billion from ¥1.55 billion previously. Net income attributable to shareholders of the parent company grew modestly by 5.2% to ¥1.23 billion from ¥1.17 billion in the prior year.
The company also noted that comprehensive income declined significantly by 43.3% to ¥674 million in the current reporting period, down from ¥1.19 billion in the comparable quarter of the previous fiscal year. On a per-share basis, net income for the third quarter was ¥57.60 per share, up slightly from ¥55.08 in the same quarter last year.
Regarding the company’s financial position as of December 31, 2025, total assets stood at ¥11.75 billion, an increase from ¥10.91 billion at the end of the previous fiscal year. Equity rose to ¥7.41 billion from ¥6.93 billion, maintaining a solid equity ratio of 63.1%.
Matsuya R&D did not declare any interim dividends during the first two quarters of the current fiscal year and does not plan to distribute an annual dividend for the fiscal year ending March 2026 due to the pending tender offer by Omron Healthcare Co., Ltd. for the company's common shares. This decision aligns with the announcement made on December 15, 2025, regarding the revision of the final dividend forecast for the fiscal year ending March 2026.
Looking ahead, Matsuya R&D projects full-year consolidated revenues of ¥9.60 billion for the fiscal year ending March 2026, representing a marginal growth of 0.3% over the previous fiscal year. The company anticipates operating profit to rise by 2.4% to ¥2.00 billion, while ordinary profit is expected to grow by 1.2% to ¥2.08 billion. Net income attributable to shareholders of the parent company is forecasted to increase by 2.7% to ¥1.60 billion, translating to an estimated earnings per share of ¥75.12.
These projections reflect no changes from the most recent forecasts released by the company. However, it should be noted that these forward-looking statements are based on currently available information and certain assumptions deemed reasonable by management. Actual results may vary significantly due to various factors beyond the company's control.
AI-translated content. 🟢 Confidence: High See terms • Original filing